Table 6.
Comparison of participant characteristics, study design, and results between the present study and the Mapstone study [12]
| Characteristics | Mapstone (discovery) | Present study |
|---|---|---|
| Participants with normal cognition at baseline | 53 | 221 |
| Participants with amnestic MCI (aMCI) or AD at baseline | 35 | None |
| Participants with samples collected at both the baseline (pre) and follow-up (post) | 18 (Converters) | 221 |
| Partcipants who developed aMCI or AD at the follow-up | 18 (Converters) | 95 |
| Characteristics | Normal (53) | aMCI/AD (35) | Converters (18) | Normal (126) | MCI (77) | Dementia (18) |
|---|---|---|---|---|---|---|
| Age (years), baseline | 81.6 (3.6) | 82.3 (4.8) | 80.2 (3.0) | 70.9 (3.6) | 71.3 (3.7) | 73.1 (5.0) |
| % Female | 66.0% | 71.4% | 55.6% | 66.7% | 62.3% | 77.8% |
| % African American | Not reported | 96.8% | 96.1% | 100.0% | ||
| Education | ||||||
| Mean, years | 15.68 (2.32) | 15.45 (2.19) | 15.33 (3.14) | Not reported | ||
| % high school graduate | Not reported | 21.40% | 32.50% | 33.30% | ||
| Follow-up interval, mean, years (range) | 2.1 (1–5) | 7.3 (5.8–8.6) | ||||
| Sample for metabolomic analysis | Plasma | Plasma | ||||
| Metabolomics method | p180 kits (Biocrates) | p180 kits (Biocrates) | ||||
| Performance of the 10-metabolite panel described in the Mapstone study | ||||||
| Normal versus Converter (pre) AUC | 0.96 | 0.609∗ | ||||
| Normal versus aMCI/AD AUC | 0.827 | 0.607† | ||||
∗
Including nine metabolites instead of 10 because C16:1-OH levels were lower than LOD in all participants in the present study.
†
For the present study, this reflects normal versus MCI/dementia at the follow-up visit.